Join the 'Metformin' group to help and get support from people like you.

Metformin Blog

FDA Approves Invokamet (canagliflozin/metformin) for Type 2 Diabetes

Posted 11 Aug 2014 by Drugs.com

RARITAN, N.J., August 8, 2014 – Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved Invokamet, a fixed dose therapy combining canagliflozin and metformin hydrochloride in a single tablet, for the treatment of adults with type 2 diabetes. Invokamet provides the clinical attributes of Invokana (canagliflozin), the first sodium glucose co-transporter 2 (SGLT2) inhibitor available in the United States, together with metformin, which is commonly prescribed early in the treatment of type 2 diabetes. Invokamet is the first fixed-dose combination of an SGLT2 inhibitor with metformin approved in the United States. "Invokamet combines, in one tablet, two complementary therapeutic approaches proven effective for managing type 2 diabetes,” said Richard Aguilar, M.D.*, Medical Director of Diabetes Nation. "Canagliflozin works with the kidney to pro ... Read more

Related support groups: Diabetes, Type 2, Metformin, Invokana, Canagliflozin

Blacks May Respond Better Than Whites to Diabetes Drug Metformin

Posted 12 Jun 2014 by Drugs.com

THURSDAY, June 12, 2014 – Blacks with type 2 diabetes may fare better on the widely used drug metformin compared with whites, a new study finds. Researchers analyzed data from more than 19,600 Americans who were prescribed metformin between 1997 and 2013. The team found that blacks had greater improvements in their blood sugar control than whites. Study participants underwent at least two A1C blood tests at least four months apart while they took metformin. An A1C test measures a person's average blood sugar level over the previous three months. The maximum dose of metformin was associated with a 0.9 percent decrease in A1C results among blacks, compared with a 0.42 percent decrease among whites – a significant improvement. The study is published online June 12 in the Journal of Clinical Endocrinology & Metabolism. "Metformin is normally the first treatment physicians prescribe for ... Read more

Related support groups: Diabetes, Type 2, Metformin, Glucophage, Glucophage XR, Glumetza, Fortamet, Riomet

Insulin-Metformin Combo Tied to Poorer Survival in Diabetes Study

Posted 10 Jun 2014 by Drugs.com

TUESDAY, June 10, 2014 – The combination of metformin and insulin for people with type 2 diabetes may slightly increase death rates among patients, according to researchers from Vanderbilt University. However, other experts question the study's conclusions and claim it is at odds with other better-designed studies that show the combination of metformin and insulin is both safe and effective. "Insulin remains a reasonable option for patients who have very high glucose [blood sugar] or who desire flexible and fast blood sugar control, but most patients taking metformin prefer to delay starting insulin," said lead researcher Dr. Christianne Roumie, an associate professor of internal medicine and pediatrics at Vanderbilt University in Nashville, Tenn. "The current study suggests that adding a sulfonylurea to metformin should be preferred to adding insulin for most patients who need a ... Read more

Related support groups: Diabetes, Type 2, Metformin, Glucophage, Glucophage XR, Glumetza, Fortamet, Riomet

Diabetes Treatment Falls Short as Heart Failure Drug in Study

Posted 31 Mar 2014 by Drugs.com

MONDAY, March 31, 2014 – A drug commonly used to treat diabetes does not help prevent heart failure in non-diabetics who've had a heart attack, according to a new study. Researchers said results from the rigorous clinical trial dispute previous findings that showed the drug, metformin, could have a protective effect on the heart. "While this glucose-lowering drug is very effective in patients with diabetes and can be safely used in patients with a heart attack, [our data show] it is not of additional benefit in protecting the heart from damage resulting in decreased pump function of the heart," said the study's lead investigator, Dr. Chris Lexis, of University Medical Center Groningen in the Netherlands. Heart attacks often damage heart muscle, which leads to reduced functioning of the left ventricle. This affects the ability of the heart to pump blood. Several animal studies have ... Read more

Related support groups: Diabetes, Type 2, Metformin, Heart Attack, Heart Failure, Congestive Heart Failure, Glucophage, Myocardial Infarction, Glucophage XR, Glumetza, Fortamet, Riomet

Diabetes Drugs Affect Hearts of Men, Women Differently

Posted 16 Dec 2013 by Drugs.com

MONDAY, Dec. 16, 2013 – Widely used diabetes drugs have different effects on men's and women's hearts, a new study suggests. Researchers examined how three commonly prescribed treatments for type 2 diabetes affected 78 patients who were divided into three groups. One group took metformin alone, the second group took metformin plus rosiglitazone (sold under the brand name Avandia) and the third group took metformin plus Lovaza, a type of fish oil. Metformin reduces blood sugar production by the liver and improves insulin sensitivity. Rosiglitazone also improves insulin sensitivity and moves free fatty acids out of the blood. Lovaza lowers blood levels of another type of fat called triglycerides. The researchers found that the drugs had very different and sometimes opposite effects on the hearts of men and women, even as the drugs controlled blood sugar equally well in both genders. The ... Read more

Related support groups: Diabetes, Type 2, Metformin, Glucophage, Lovaza, Fish Oil, Avandia, Glucophage XR, Omega-3, Glumetza, Rosiglitazone, Omacor, Omega-3 Polyunsaturated Fatty Acids, Fortamet, Riomet, MaxEPA, Animi-3, Marine Lipid Concentrate, Proepa, Sea-Omega, Divista

Diabetes Drug Metformin Tied to Slight Weight Loss in Obese Kids

Posted 16 Dec 2013 by Drugs.com

MONDAY, Dec. 16 – Obese children who don't have type 2 diabetes but take the diabetes drug metformin while improving their diet and exercise habits seem to lose a bit of weight. But it isn't much more weight than kids who only make the lifestyle changes, according to a new review of studies. Some evidence suggests that metformin, in combination with lifestyle changes, affects weight loss in obese children. But the drug isn't likely to result in important reductions in weight, said lead researcher Marian McDonagh. Childhood obesity is a significant health problem in the United States, with nearly 18 percent of kids between 6 and 19 years old classified as obese. Metformin is approved by the U.S. Food and Drug Administration to treat type 2 diabetes in adults and children over 10 years old, but doctors have used it "off-label" to treat obese kids who don't have diabetes, according to ... Read more

Related support groups: Obesity, Metformin, Glucophage, Glucophage XR, Glumetza, Fortamet, Riomet

Metformin Won't Help Heart Patients Without Diabetes: Study

Posted 6 Nov 2013 by Drugs.com

WEDNESDAY, Nov. 6 – A new clinical trial appears to have dashed hopes that the most popular drug for treating type 2 diabetes might also be able to reduce the risk of heart attack and stroke in nondiabetics. Previously, diabetes patients who took metformin, a safe and effective blood sugar-lowering pill, experienced a 39 percent lower risk of heart attack over 10 years in a landmark drug trial in the United Kingdom. Based on those findings, researchers with the University of Glasgow, in Scotland, set out to see whether metformin would provide similar cardiovascular benefits for people who don't have diabetes. The new results, published online Nov. 7 in The Lancet Diabetes & Endocrinology, are disappointing, the study authors said. "We didn't find that any markers of heart risk really looked like they improved in any meaningful way," said study leader Dr. David Preiss, a clinical senior ... Read more

Related support groups: Diabetes, Type 2, Metformin, Glucophage, Glucophage XR, Glumetza, Fortamet, Riomet

Common Diabetes Drugs May Carry Risk, Study Suggests

Posted 26 Sep 2013 by Drugs.com

THURSDAY, Sept. 26 – Diabetes patients who take drugs called sulfonylureas as an initial therapy have a higher risk of death than those who take the diabetes drug metformin, a new study says. The British researchers said the findings suggest that it may no longer be appropriate to offer sulfonylureas as a first-line treatment. Diabetes experts in the United States agreed that the study could have an impact on care. The findings "will change the practice of glucose [blood sugar]-lowering therapy," said Dr. Spyros Mezitis, an endocrinologist at Lenox Hill Hospital in New York City. But he added that "more study is need to confirm this data," and use of the alternative drug, metformin, is not always the answer. "Metformin and other oral hypoglycemic agents have their drawbacks, and probably we will see earlier use of insulin in type 2 diabetics," Mezitis said. Both metformin (brand names ... Read more

Related support groups: Diabetes, Type 2, Metformin, Glucophage, Glipizide, Glyburide, Glimepiride, Amaryl, Glucophage XR, GlipiZIDE XL, Glucotrol, Glumetza, Glucotrol XL, Riomet, Fortamet, DiaBeta, Glynase, Micronase, Tolazamide, Chlorpropamide, Diabinese

Metformin May Lower Risk of Prostate Cancer Death, Researchers Say

Posted 5 Aug 2013 by Drugs.com

MONDAY, Aug. 5 – Metformin, a widely used diabetes drug, may reduce the risk of dying from prostate cancer, according to new research. A study of nearly 4,000 diabetic men found that those taking metformin when diagnosed with prostate cancer were less likely to die of the cancer or other causes compared to men using other diabetes drugs. "We demonstrated that metformin is associated with improved survival among diabetic patients with prostate cancer," said Dr. David Margel, a uro-oncologist at Rabin Medical Center in Petah Tikva, Israel, who conducted the research while at the University of Toronto. "It's associated in a dose-response manner," he said. "The longer you were on metformin, the less likely you were to die of prostate cancer and of all causes." But whether metformin can prevent prostate cancer progression in people without diabetes remains to be seen, experts say. Diabetes ... Read more

Related support groups: Metformin, Prostate Cancer, Glucophage, Glucophage XR, Glumetza, Fortamet, Riomet

In Mice, Diabetes Drug Metformin Tied to Longer, Healthier Lives

Posted 30 Jul 2013 by Drugs.com

TUESDAY, July 30 – A new study in mice hints that the widely used diabetes drug metformin might have life-extending benefits beyond its effects on diabetes. The study found that a small dose of metformin, given regularly in middle age, boosted the health of mice and extended their lives, while a larger dose shortened their lives. "Aging is a driving force behind metabolic syndrome and diabetes. Given that metformin is clinically proven to alleviate symptoms of these conditions, and reduce risk of cancer, we thought perhaps it was a good candidate to study for its broader effects on health and lifespan," study leader Rafael de Cabo, of the U.S. National Institute on Aging (NIA), explained in a U.S. National Institutes of Health news release. The drug was given to the mice beginning in middle age and two doses of metformin – 0.1 percent and 1 percent – were tested by the international ... Read more

Related support groups: Metformin, Glucophage, Glucophage XR, Glumetza, Fortamet, Riomet

Diabetes Drug May Protect the Brain

Posted 15 Jul 2013 by Drugs.com

MONDAY, July 15 – The diabetes drug metformin may do more than help control blood sugar levels: New research suggests it may also reduce the risk of dementia. Compared to people taking another class of diabetes medications called sulfonylureas, those taking metformin had a 20 percent reduced risk of developing dementia over the five-year study period. "Metformin could have a possible neuroprotective effect in the brain," said study author Dr. Rachel Whitmer, an epidemiologist in the division of research at Kaiser Permanente in Oakland, Calif. Whitmer, however, added a caveat: "This was an observational, retrospective, population-based study. We found an association, but didn't prove cause and effect." Whitmer is scheduled to present the findings Monday at the Alzheimer's Association International Conference in Boston. Research presented at medical meetings should be viewed as ... Read more

Related support groups: Diabetes, Type 2, Metformin, Glucophage, Glucophage XR, Glumetza, Fortamet, Riomet

Metformin Won't Aid Breast Cancer Survival in Diabetics

Posted 14 May 2013 by Drugs.com

TUESDAY, May 14 – Despite prior research suggesting that the widely used diabetes drug metformin might help cancer patients, a new study finds it does not boost survival for older breast cancer patients with diabetes. Previous research has found that metformin was associated with an up to 30 percent reduction in new cancers in breast cancer patients without diabetes, noted study author Dr. Iliana Lega, a research fellow at Women's College Hospital in Toronto. Prior research has also tied use of the drug to slowed tumor growth. "Metformin is a drug commonly used by diabetic patients to control the amount of glucose [sugar] in their blood," Lega explained in a hospital news release. "Although existing scientific literature suggests that the drug may prevent new cancers and death from breast cancer, our study found the drug did not significantly impact survival rates in our patients." The ... Read more

Related support groups: Diabetes, Type 2, Metformin, Breast Cancer, Glucophage, Diabetes, Type 1, Diabetes Mellitus, Glucophage XR, Breast Cancer, Prevention, Glumetza, Fortamet, Riomet

Antihistamines Adding to Drug Pollution in Streams

Posted 2 Apr 2013 by Drugs.com

TUESDAY, April 2 – Antihistamines and other medicines disrupt the ecosystems of streams, a new study finds. "Pharmaceutical pollution is now detected in waters throughout the world," lead author Emma Rosi-Marshall, a scientist at the Cary Institute of Ecosystem Studies in Millbrook, N.Y., said in an institute news release. "Causes include aging infrastructure, sewage overflows and agricultural runoff. Even when wastewater makes it to sewage treatment facilities, they aren't equipped to remove pharmaceuticals." "As a result, our streams and rivers are exposed to a cocktail of synthetic compounds, from stimulants and antibiotics to analgesics and antihistamines," Rosi-Marshall said. The researchers examined how some common medicines affect similar-sized streams in New York, Maryland and Indiana. The medicines included the antibiotic ciprofloxacin, the diabetes drug metformin, two ... Read more

Related support groups: Metformin, Benadryl, Cipro, Ciprofloxacin, Diphenhydramine, Zantac, Glucophage, Ranitidine, Zantac 150, Glucophage XR, Benadryl Allergy, Tagamet, Simply Sleep, Glumetza, Sominex, Cimetidine, Zantac 75, Nytol, Q-Dryl, Diphen

Three New Drugs Approved for Type 2 Diabetes

Posted 30 Jan 2013 by Drugs.com

MONDAY, Jan. 28 – Three new related drugs designed to improve blood sugar control in people with type 2 diabetes have been approved by the U.S. Food and Drug Administration. All three drugs contain a new active ingredient, alogliptin (brand named Nesina), either by itself or with other previously approved medications. In addition to Nesina, the agency approved Kazano (alogliptin and metformin hydrocholoride) and Oseni (alogliptin and pioglitazone). Type 2 diabetes leads the body to resist insulin or to produce insufficient amounts of the hormone, causing blood sugar to spike. The disease affects about 24 million people in the United States, accounting for more than 90 percent of diabetes cases, the FDA said in a news release. Nesina, either by itself or in combination with other medications, was tested in 14 clinical studies involving some 8,500 people with type 2 diabetes. The new ... Read more

Related support groups: Diabetes, Type 2, Metformin, Pioglitazone, Metformin/Pioglitazone

Takeda Receives FDA Approval for Kazano (alogliptin and metformin) for Type 2 Diabetes

Posted 28 Jan 2013 by Drugs.com

DEERFIELD, Ill. and OSAKA, Japan, Jan. 25, 2013 /PRNewswire/ – Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Kazano (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise. "Takeda is pleased with the FDA approval of Kazano for the treatment of type 2 diabetes, a therapeutic category in which we have more than twenty years of clinical and patient experience," said Douglas Cole, president, Takeda Pharmaceuticals U.S.A., Inc. "Millions of people are affected by diabetes and, as a leader in the diabetes arena, Takeda is dedicated to working to advance patient care and helping to meet the needs of this growing patient population." Kazano contains alogliptin, a dipeptidyl ... Read more

Related support groups: Diabetes, Type 2, Metformin

Page 1 2 3 4 Next

Ask a Question

Further Information

Related Condition Support Groups

Polycystic Ovary Syndrome, Diabetes, Type 2, Insulin Resistance, Female Infertility

Related Drug Support Groups

Glucophage, Glucophage XR, Glumetza, Riomet, Fortamet

Metformin Patient Information at Drugs.com